It is not a legitimate therapeutic in any regulatory sense
Identified in early research literature under the developmental code TH9507, tesamorelin received regulatory approval under the brand name Egrifta for clinical indications outside the scope of research-use-only material
Monitor Results: Results may not be immediately visible and may vary from person to person
[6] These findings support the interpretation that NO-related pathways may contribute to some observed BPC-157-associated effects in laboratory systems, but they do not prove that BPC-157 directly binds NOS enzymes or directly controls NO production
It: Stimulates collagen and elastin synthesis Supports extracellular matrix remodeling Helps regulate inflammation pathways Encourages antioxidant defense activity In practical terms, this translates to improved skin density, reduced fine lines, accelerated recovery from UV damage, and a measurable increase in skin firmness over 812 weeks of consistent use
Shop By Brand We stock the industrys favourite brands, trusted by aesthetic professionals